Komori Shota, Tsuboi Takashi, Suzuki Masashi, Nakamura Tomohiko, Katsuno Masahisa
Department of Neurology, Nagoya University.
Department of Neurology, Hamamatsu University Hospital.
Rinsho Shinkeigaku. 2022 Aug 27;62(8):627-631. doi: 10.5692/clinicalneurol.cn-001740. Epub 2022 Jul 22.
We present a 71-year-old woman with an eight-year history of Parkinson's disease (PD). She began to experience wearing-off at the age of 66 and subsequently developed dyskinesia. She had worsened dyskinesias for three days, followed by a high fever, and she was subsequently hospitalized. On admission, severe dyskinesia, hyperpyrexia, and elevation of serum creatine kinase were observed. Severe dyskinesia without rigidity continued throughout the day and she was diagnosed with dyskinesia-hyperpyrexia syndrome (DHS). She was treated with standard medical care and anti-parkinsonian medications were reduced drastically. Dyskinesia started to wane three days after admission and almost disappeared on day twelve. Prior to admission, the patient reported she had been taking two to three times the dose prescribed of istradefylline, which was the suspected to be a trigger of DHS. Because DHS is a rare but potentially life-threatening complication, early recognition and diagnosis is vital. A proper treatment strategy for DHS may include standard medical care together with reduced anti-parkinsonian medications.
我们报告一位71岁患有帕金森病(PD)8年的女性患者。她在66岁时开始出现疗效减退,随后发展为异动症。她的异动症恶化了三天,接着出现高热,随后住院治疗。入院时,观察到严重的异动症、高热以及血清肌酸激酶升高。全天持续存在无强直的严重异动症,她被诊断为异动症-高热综合征(DHS)。她接受了标准的医疗护理,抗帕金森病药物剂量大幅减少。入院三天后异动症开始减轻,在第12天几乎消失。入院前,患者报告她服用的异他司琼剂量是规定剂量的两到三倍,这被怀疑是DHS的触发因素。由于DHS是一种罕见但可能危及生命的并发症,早期识别和诊断至关重要。DHS的适当治疗策略可能包括标准医疗护理以及减少抗帕金森病药物的使用。